Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 14/20 | 0.73 |
| ▸ | NFE2L2 | Q16236 | 14/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366699 | 0.87 | KEAP1 (0.54) | KEAP1NFE2L2PPARGHCRTR2PTGER1 | |
| SCHEMBL699184 | 0.80 | KEAP1 (0.88) | KEAP1NFE2L2PPARG | |
| SCHEMBL3366459 | 0.79 | KEAP1 (0.86) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL1632092 | 0.79 | KEAP1 (0.86) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL3367297 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL3367300 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL1039483 | 0.77 | KEAP1 (0.81) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL24279587 | 0.76 | KEAP1 (0.65) | KEAP1NFE2L2PPARGHCRTR2PTGER1 | |
| SCHEMBL3366742 | 0.75 | KEAP1 (0.77) | KEAP1NFE2L2PPARGHCRTR2 | |
| SCHEMBL364573 | 0.75 | FFAR1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | KEAP1 2923/4885NFE2L2 1276/4885PPARG 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.